Apixaban plus P2Y12 inhibitor ‘likely best’ for AF after cardiac events
Antithrombotic regimen can be safely used 'across the spectrum of risks', researchers say
Apixaban plus a P2Y12 inhibitor without aspirin is a superior antithrombotic therapy in patients with AF after acute coronary syndromes or percutaneous coronary intervention, researchers say.
Their post-hoc analysis of the large, open-label AUGUSTUS trial indicates that this regimen was beneficial in this cohort, regardless of baseline risk of bleeding or stroke.
